Upadacitinib

English Name: ApalutamideEnglish AliasesARN-509; AR509; ARV-509; 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspirooctan-5-yl)-2-fluoro-N-methylbenzamide; Benzamide,4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-
C...

Product name: Finerenone
Alias: Finerenone (BAY94-8862); (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide; (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide; BAY94-8862; BAY948862; 1,6-Naphthyridine-3-...

Product name:  Orforglipron

Alias: 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-teChemicalbooktrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5...

product name: Suzetrigine

Synonyms: 2-Pyridinecarboxamide,4-[[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-;Suzetrigine;VX-548（Suzetrigine）;4-[(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trif...

We are proud to announce that our pharmaceutical ingredient Tetracaine Hydrochloride has been granted the Certificate of Suitability to the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines (EDQM) on August 20, 2025. This marks a significant milestone as we become the first company in China and one of only three global manufacturers to hold this certification for this critical local anesthetic.

Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates , CDMO/CRO/OEM, and Technology Transfer of Finished Formulations. With 23 years of production experience, the company operates 6 GMP-compliant workshops, achieving a monthly capacity of 100 tons to meet cGMP requirements. Currently, the factory has registered 27 APIs in NMPA, filed 4 US-DMFs, and applied for 8 CEPs, while successfully passing audits by MFDS, US FDA, and global customers.

On 3 January 2025, our API Articaine Hydrochloride obtained the Certificate of Suitability for European Pharmacopoeia (CEP Certificate) issued by the European Directorate for the Quality of Medicines (EDQM). This is the third CEP certificate for our company, and we are the first company in China (9 companies in the world) to obtain the CEP certificate for Articaine Hydrochloride. 

The main production and R & D varieties of local anesthesia, antiviral drugs, cardiovascular and cerebral vascular system, antitumor drugs, digestive drugs, diabetes, veterinary drugs, CDMO products.